Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Liquidia Corporation

Liquidia Corporation is a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease. The company's current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT® Technology.

Liquidia Corporation | 7,350 followers on LinkedIn. A biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease.  | Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and other applications of its PRINT® Technology. Liquidia has developed YUTREPIA™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Liquidia is also developing L606, an investigational liposomal formulation of treprostinil administered twice-daily with a short-duration next-generation nebulizer, for use in North America.

Chief Operating Officer at OA Private Capital (“OAPC”) / RDV Affiliate

Damian deGoa

I elevate healthcare leaders, brands, products and initiatives using smart communications strategies that make a measurable impact.

Patrick Wallace

Providing GxP Compliance Expertise and Leadership

David Dumers

Kristan Amicone

Liquidia Corporation (NASDAQ: LQDA) announced today it will report its third quarter 2024 financial results on November 13, 2024. The company will host a live webcast at 8:30 a.m. Eastern Time to discuss its financial results and to provide a corporate update. Click here for more information: https://bit.ly/3NUfe8j

At Liquidia, we’re proud to support Pulmonary Hypertension Awareness Month throughout the month of November. Join us in our efforts to raise awareness about pulmonary hypertension and learn how members of the PH community are letting their light shine. Visit the Pulmonary Hypertension Association here for more information: https://bit.ly/2IfiVXh #PHAwarenessMonth #LetYourLightShine

Did you know that #PHILD can lead to increased pulmonary vascular resistance and right heart failure? This condition complicates ILD, making early diagnosis and advanced therapies crucial for improving patient outcomes. At Liquidia, we're working to develop novel treatments for #PAH and PH-ILD patients in need. Learn more about our work here: https://bit.ly/3zpBPWt

It truly takes a team to accomplish fetes such as these! Congratulations to Team PHenomenal Hope ( #TeamPH ), its #LetMeBeYourLungs team and Liquidia’s very own Jessica Ashbaucher . Together, they took on the arduous task of climbing to #MountEverest Base Camp to help raise awareness and critical research funds for the benefit of the #pulmonaryhypertension community. On behalf of all of us at Liquidia, we salute you!

The Liquidia team consists of industry-leading scientists, clinicians, business strategists, engineers, & pharmaceutical executives, working together to help people lead longer, healthier, and happier lives. By combining our diverse expertise, we’re pushing the boundaries of innovation in healthcare, working to develop solutions that make a real difference in patients' lives. Learn more: https://lnkd.in/ga5DV4xd

Today we announced that the U.S. Supreme Court has rejected a request to appeal prior decisions around a patent for a competing product. Our CEO, Roger Jeffs said, "We are pleased that the Supreme Court has denied the petition by United Therapeutics and affirmed previous rulings that every claim of the ‘793 patent is invalid. We are grateful that this specific chapter has come to a close and that the ‘793 patent will now be forever unenforceable. We will continue to fight for the earliest possible launch of YUTREPIA so that patients and physicians have access to the unique benefits that YUTREPIA can provide." Read more in our press release: https://bit.ly/4eTtR75

October is #HealthyLungMonth , a reminder to take care of the organs that power every breath. At Liquidia, we're committed to advancing innovative treatments for those facing rare cardiopulmonary diseases like #PAH and #PHILD . Check out these tips from American Lung Association for keeping your lungs healthy: https://bit.ly/4gQaayQ

Today we announced an expanded collaboration with Pharmosa Biopharm Inc (Pharmosa) for the development and commercialization of L606, an investigational, inhaled, sustained-release formulation of #treprostinil currently being evaluated in a clinical trial for the treatment of pulmonary arterial hypertension ( #PAH ) and pulmonary hypertension associated with interstitial lung disease ( #PHILD ). For more information, see today’s press release: https://bit.ly/47SOq1b

	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue	13.22M -	7.26M 45.08%	2.71M 62.70%	8.07M 198.20%	739.63K 90.84%	12.85M 1,637.81%	15.94M 23.98%	17.49M 9.75%
cost of revenue	918.78K -	319.76K 65.20%	121.39K 62.04%	807.19K 564.95%	237.71K 70.55%	3.02M 1,171.67%	2.86M 5.42%	4.07M 42.22%
gross profit	12.30M -	6.94M 43.58%	2.59M 62.73%	7.26M 180.98%	501.92K 93.09%	9.83M 1,858.58%	13.08M 33.02%	13.42M 2.65%
selling and marketing expenses
general and administrative expenses	4.84M -	10.21M 110.96%	8.75M 14.28%	13.60M 55.32%	27.37M 101.28%	23.11M 15.56%	32.41M 40.24%	44.74M 38.05%
selling general and administrative expenses	4.84M -	10.21M 110.96%	8.75M 14.28%	13.60M 55.32%	27.37M 101.28%	23.11M 15.56%	32.41M 40.24%	44.74M 38.05%
research and development expenses	23.32M -	24.75M 6.15%	28.70M 15.94%	40.49M 41.09%	32.22M 20.42%	20.52M 36.33%	19.43M 5.27%	42.06M 116.43%
other expenses								-1.18M -
cost and expenses	29.08M -	35.29M 21.34%	37.58M 6.49%	54.90M 46.10%	59.83M 8.99%	46.65M 22.03%	54.70M 17.27%	90.87M 66.11%
operating expenses	28.16M -	34.97M 24.17%	37.45M 7.11%	54.09M 44.41%	59.59M 10.17%	43.63M 26.79%	51.85M 18.84%	86.81M 67.43%
interest expense	85.86K -	13.01M 15,052.24%	18.99M 45.95%	1.37M 92.77%	858.00K 37.54%	815.04K 5.01%	2.34M 186.86%	6.27M 168.31%
ebitda	-15.20M -	-27.10M 78.31%	-33.02M 21.86%	-46.21M 39.95%	-58.90M 27.47%	-33.76M 42.68%	-37.68M 11.60%	-71.21M 88.98%
operating income	-15.86M -	-28.03M 76.69%	-34.87M 24.40%	-46.82M 34.29%	-59.09M 26.20%	-33.80M 42.80%	-38.77M 14.71%	-73.38M 89.28%
depreciation and amortization	651.56K -	931.93K 43.03%	1.54M 65.64%	613.72K 60.24%	184.36K 69.96%	33.44K 81.86%	1.09M 3,160.06%	2.18M 99.82%
total other income expenses net	-70.96K -	11.88M 16,848.06%	415.41K 96.50%	-759.91K 282.93%	-673.64K 11.35%	-781.61K 16.03%	-2.25M 187.23%	-5.12M 127.97%
income before tax	-15.93M -	-29.15M 82.97%	-53.14M 82.26%	-47.58M 10.45%	-59.76M 25.60%	-34.58M 42.14%	-41.02M 18.61%	-78.50M 91.40%
income tax expense	14.91K -	13.01M 87,183.48%	720.39K 94.46%	-1.19M 265.76%	-2.27M 90.23%	-4.80M 111.17%	-2.65M 44.76%	-2.18M 17.81%
net income	-15.93M -	-29.15M 82.97%	-53.14M 82.26%	-46.39M 12.70%	-57.49M 23.93%	-29.78M 48.20%	-38.37M 28.82%	-78.50M 104.62%
weighted average shs out	5.09M -	8.59M 68.77%	7.16M 16.58%	18.48M 158.02%	33.89M 83.35%	49.68M 46.59%	60.96M 22.71%	64.99M 6.62%
weighted average shs out dil	5.09M -	8.59M 68.77%	7.16M 16.58%	18.48M 158.02%	33.89M 83.35%	49.68M 46.59%	60.96M 22.71%	64.99M 6.62%
eps	-3.13 -	-3.40 8.63%	-7.42 118.24%	-2.51 66.17%	-1.70 32.27%	-0.60 64.71%	-0.63 5.00%	-1.21 92.06%
epsdiluted	-3.13 -	-3.40 8.63%	-7.42 118.24%	-2.51 66.17%	-1.70 32.27%	-0.60 64.71%	-0.63 5.00%	-1.21 92.06%

COM:LIQUIDIA

Liquidia Corporation

Last Close

10.15

22/11 21:00

Market Cap

955.17M

Beta: -

Volume Today

1.05M

Avg: -

Preview